We're attending the UK Clinical Vaccine Network Conference 2025
Are you ready to leave freezer logistics behind? Thursday 12 June at the UK Clinical Vaccine Network Conference, our CEO, Dr Andrew Goldsborough, will unveil TheraPHIX™—an ambient-temperature, liquid-stable mRNA-LNP platform designed to simplify vaccine delivery and remove cold-chain barriers.
One of the biggest challenges in rolling out modern mRNA therapeutics is maintaining ultra-low temperatures from production to patient. TheraPHIX™ addresses this by preserving lipid nanoparticle integrity at room temperature, cutting out dry ice, specialised freezers and emergency power backups. That means faster distribution, lower costs and reliable access to advanced vaccines in every setting.
At 15:45 on Thursday 12 June, Dr Goldsborough will share detailed stability data, fill–finish process optimisations and real-world case studies that demonstrate how TheraPHIX™ delivers consistent potency for weeks without refrigeration. He’ll also explain how our platform slots seamlessly into existing mRNA manufacturing workflows, minimising new capital expenditure and accelerating time to clinic.
Whether you work in vaccine design, process development or supply chain management, you’ll come away with actionable insights to improve shelf life, reduce logistical complexity and expand reach into regions where refrigeration can’t be taken for granted.
If you’re attending the session, we’d love to meet you in person—find us afterwards on the Cutler’s Hall exhibition floor or drop by our virtual booth online to talk collaboration, pilot studies or licensing opportunities. Let’s work together to make mRNA medicines practical, scalable and accessible around the world.
Event details
What: UK Clinical Vaccine Network Conference 2025
When: 12 June 2025, 15:45 (vaccine manufacturing & design session)
Where: Cutler’s Hall, Sheffield, UK & online
